Cardioprotective efficacy depends critically on pharmacological dose, duration of ischaemia, health status of animals and choice of anaesthetic regimen: a case study with folic acid

Table 1 Baseline parameters of isolated heart experiments

Group	Flow (ml/min/g)	EDP (mmHg)	Psys (mmHg)	Heart rate (beats/min)	RPP(10³ mmHg/min)
WT, 25 min I, 0 FA	12.7 ± 0.3	8.0 ± 0.7	99 ± 9	366 ± 3	33.4 ± 3.3
WT, 25 min I, 1 FA	10.9 ± 0.2	8.0 ± 0.8	91 ± 2	415 ± 27	34.3 ± 1.6
WT, 25 min I, 5 FA	9.2 ± 0.3	7.0 ± 0.4	95 ± 6	364 ± 14	32.1 ± 3.2
WT, 25 min I, 50 FA	10.2 ± 0.7	7.3 ± 0.2	102 ± 4	366 ± 24	35.1 ± 3.5
WT, 35 min I, 0 FA	12.0 ± 0.5	4.4 ± 0.7	119 ± 4	356 ± 12	40.6 ± 1.9
WT, 35 min I, 5 FA	12.4 ± 1.0	6.0 ± 0.3	114 ± 4	346 ± 26	36.8 ± 1.7
WT, 35 min I, 50 FA	11.7 ± 1.4	5.0 ± 1.1	121 ± 7	382 ± 9	44.2 ± 2.9
WT, 35 min I, 100 FA	10.1 ± 0.7	5.7 ± 1.2	107 ± 3	347 ± 20	35.6 ± 3.2
eNOS^−/−, 25 min I, 0 FA	12.7 ± 1.4	5.1 ± 1.9	113 ± 6	383 ± 24	41.8 ± 4.8
eNOS^−/−, 25 min I, 50 FA	11.0 ± 1.4	5.2 ± 0.6	107 ± 6	356 ± 29	36.7 ± 3.9

WT, wild-type; 0-1- 5-50-100 FA, 0-1-5-50-100 μM Folic Acid; ml/min/g, ml perfusate per min per g heart wet weight; EDP, end-diastolic pressure; Psys, peak systolic pressure; RPP, rate pressure product. No differences among groups were detected. Mean ± SEM.

ISSN: 1479-5876